|
Current methods of imaging are limited in terms of the information provided to oncologists and surgeons. Enlyton's proprietary molecular targets generate images in PET/CT that more accurately reflect the extent of cancer, thus enabling oncologists and surgeons to better determine the order of therapy and predict the outcome of disease.
|
|
Contact
Us
Enlyton has demonstrated efficacy for the use of its first cancer targeting agent,
ATA-1, in PET/CT, and is presently validating this product for near term use in clinical trials.
CEO: Jeff Bergen
Jeff.Bergen@enlyton.net
COO: Ted Martin
Ted.Martin@enlyton.net
|